Can patient-specific molecular or immunometabolic profiles predict responsiveness to SGLT2 inhibitors, GLP-1 receptor agonists, RAAS modulators, or anti-inflammatory therapies during COVID-19? This evidence concerns the gene SLC5A2 and COVID-19.